# Starbloom Capital

> Starbloom Capital is a VC fund backing Biotechnology and Health Care. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 12
- Last investment: Mar 2026
- Lead investor: 33%
- Last updated: Aug 2026

Starbloom Capital is an investment firm.

## Contacts

5 contacts available for Starbloom Capital. Shizune tracks 1 team members at Starbloom Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/starbloom-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 50% |
| Health Care | 4 | 33% |
| Medical | 2 | 17% |
| Biopharma | 2 | 17% |
| Life Science | 2 | 17% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 6 | 50% |
| Series A | 2 | 17% |
| Pre-Seed | 1 | 8% |
| Series B | 1 | 8% |
| Series C | 1 | 8% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 67% |
| United Kingdom | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| James Fickel | Investor | 5 | https://shizune.co/investors/profile/james-fickel-9af8 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies designed to treat neurodegenerative diseases by stimulating specific brain activity patterns. The company focuses on noninvasive therapeutic systems that use synchronized visual and auditory stimulation to influence neural activity associated with cognitive function and brain health. Itstechnology platform, Spectris, is designed to evoke gamma-frequency brain waves, which play a role in learning, memory, and communication between neurons. The platform delivers controlled light and sound signals through a wearable device to trigger gamma oscillations in the brain, a pattern of neural activity that is disrupted in conditions such as Alzheimer’s disease. By restoring this activity, the therapy aims to support processes related to synaptic function, myelin integrity, and neural connectivity.Cognito Therapeutics conducts clinical research and trials to evaluate how its neuromodulation technology affects cognitive performance, brain structure, and functional abilities in patients with neurodegenerative disorders. The company studies the biological effects of sensory stimulation on brain pathways, immune responses, and neural signaling networks associated with disease progression. Through its research programs and device development, Cognito Therapeutics produces medical technologies intended for clinical treatment and investigation of neurological conditions that affect memory, cognition, and daily functioning. | $105M | Series C | Mar 05, 2026 |  |
| 0xbow | 0xbow is an Ethereum privacy service provider that primarily offers support for Sky’s USDS stablecoin, delivering secure, confidential, and user-friendly transaction solutions within the decentralized finance ecosystem. | $3.5M | Seed | Nov 18, 2025 |  |
| Adaptyx Biosciences | Adaptyx Biosciences develops wearable sensors. | $14M | Seed | Oct 20, 2025 |  |
| Bexorg | Bexorg is a techbio company that supports central nervous system drug discovery and development. The company uses its proprietary wet-lab platform, BrainEx, to generate human brain data. It trains predictive models and creates an AI engine to facilitate drug discovery research. | $23M | Series A | Oct 15, 2025 |  |
| LIfT BioSciences | LIfT Biosciences is a biotech company that develops allogeneic cell therapies using Immunomodulatory Alpha Neutrophils (IMANs) derived from hematopoietic or induced pluripotent stem cells. The company leverages its patented N‑LIfT platform to generate neutrophils capable of directly destroying cancer cells and reprogramming the tumormicroenvironment to enhance immune recruitment. Preclinical data have shown potent activity across multiple solid tumor types, with Phase I clinical trials in metastatic cervical and head‑and‑neck cancer planned in partnership with the University of Galway. | $13.4M | Series A | Sep 24, 2024 |  |
| Orchid | Orchid is a reproductive technology startup that is capable of detecting rare genetic disorders. Orchid’s preconception system analyzes both partners’ genomes and assesses genetic predispositions to common diseases, including heart disease, stroke, schizophrenia, Alzheimer’s disease, breast cancer, and diabetes. Orchid results are developed withworld-class experts in reproductive medicine and genetics to give its clients the most accurate results.Orchid offers a “Couple Report” that utilizes an at-home saliva test to analyze each person’s genomes to detect the probability of genetic risks, then models how their DNA together will combine in a future child. If elevated risk is detected, Orchid provides insights to help couples monitor biomarkers, adapt their diet or elect for procedures, such as in vitro fertilization. It was founded by Noor Siddiqui in 2019 and is headquartered in San Francisco, California. | $12M | Seed | Dec 05, 2023 |  |
| Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies designed to treat neurodegenerative diseases by stimulating specific brain activity patterns. The company focuses on noninvasive therapeutic systems that use synchronized visual and auditory stimulation to influence neural activity associated with cognitive function and brain health. Itstechnology platform, Spectris, is designed to evoke gamma-frequency brain waves, which play a role in learning, memory, and communication between neurons. The platform delivers controlled light and sound signals through a wearable device to trigger gamma oscillations in the brain, a pattern of neural activity that is disrupted in conditions such as Alzheimer’s disease. By restoring this activity, the therapy aims to support processes related to synaptic function, myelin integrity, and neural connectivity.Cognito Therapeutics conducts clinical research and trials to evaluate how its neuromodulation technology affects cognitive performance, brain structure, and functional abilities in patients with neurodegenerative disorders. The company studies the biological effects of sensory stimulation on brain pathways, immune responses, and neural signaling networks associated with disease progression. Through its research programs and device development, Cognito Therapeutics produces medical technologies intended for clinical treatment and investigation of neurological conditions that affect memory, cognition, and daily functioning. | $73M | Series B | Mar 22, 2023 |  |
| TBD Health | TBD Health makes at-home STD/STI screening kits that are accurate, easy to use, and built for women. | $4.4M | Seed | Jan 31, 2023 |  |
| Rysk Finance | Rysk Finance is developing a dynamic hedging vault to assist in the creation of alternative, decentralized financial assets that can be used to protect against financial market risks. The service allows customers to buy and sell options on crypto assets, giving them the opportunity to protect themselves against downturns in the market if they sodesire. | $1.4M | Pre-Seed | Jan 31, 2023 |  |
| LIfT BioSciences | LIfT Biosciences is a biotech company that develops allogeneic cell therapies using Immunomodulatory Alpha Neutrophils (IMANs) derived from hematopoietic or induced pluripotent stem cells. The company leverages its patented N‑LIfT platform to generate neutrophils capable of directly destroying cancer cells and reprogramming the tumormicroenvironment to enhance immune recruitment. Preclinical data have shown potent activity across multiple solid tumor types, with Phase I clinical trials in metastatic cervical and head‑and‑neck cancer planned in partnership with the University of Galway. | $7M | Venture - Series Unknown | Dec 19, 2022 |  |

10 of 12 investments shown.

## Co-investors
- [KIZOO Technology Capital](https://shizune.co/investors/profile/kizoo) — VC Fund, 3 deals together
- [IAG Capital Partners](https://shizune.co/investors/profile/iag-capital-partners) — VC Fund, 2 deals together
- [Alzheimer's Drug Discovery Foundation](https://shizune.co/investors/profile/alzheimers-drug-discovery-foundation) — VC Fund, 1 deal together
- [Amplify Partners](https://shizune.co/investors/profile/amplify-partners) — VC Fund, 1 deal together
- [Apollo Health Ventures](https://shizune.co/investors/profile/apollo-health-ventures) — VC Fund, 1 deal together
- [Ascensive Assets](https://shizune.co/investors/profile/ascensive-asset-management) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Starbloom Capital invest in?

Starbloom Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Starbloom Capital?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Starbloom Capital?

The team at Starbloom Capital includes James Fickel (Investor). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co